$CNXU — Tissue Regeneration / Biotech $CNXU is a Reno-based biotechnology company advancing tissue regeneration, with its lead asset being the CXU wound care device currently undergoing manufacturing scale-up and standardized formulation development with its CDMO — activities targeting a planned Q1 2027 FDA 510(k) premarket notification submission.  The company only began trading on Nasdaq as recently as May 21, 2026 , making this an extremely early-stage name. $CNXU also recently initiated a preclinical development program for its B.R.E.A.S.T.™ Bioregenerative Matrix Platform in partnership with Wake Forest Institute for Regenerative Medicine , signaling pipeline expansion beyond wound care. The key risk is glaring: the company has generated zero revenues to date and expects to continue incurring operating losses for the foreseeable future , with the balance sheet showing consulting fees and share-based compensation as primary expenses. With a ~$341M market cap and a 52-week range of $4–$18.79 , this is a high-speculation, pre-revenue micro-cap with extreme binary risk tied entirely to FDA regulatory milestones — position sizing discipline is critical here. Not financial advice. DYOR.